ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC
Results from a phase II study of bevacizumab and erlotinib [...]
Results from a phase II study of bevacizumab and erlotinib [...]
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary condition associated [...]
This interview with Dr Ramaprasad Srinivasan from the National Cancer Institute in [...]
In this video, Dr W. Marston Linehan, chief of the [...]